Topiramate versus fluvoxamine in the treatment of pathological gambling: A randomized, blind-rater comparison study

Clinical Neuropharmacology

Volumn 28, Issue 1, 2005, Pages 6-10

  Dannon, Pinhas N ^a,b   Lowengrub, Katherine ^a   Gonopolski, Yehudit ^a   Musin, Ernest ^a   Kotler, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Rehovot Community Mental Health and Rehabilitation Clinic   (Israel)

Author keywords

Fluvoxamine; Obsessive compulsive spectrum; Pathological gambling; Topiramate

Indexed keywords

FLUVOXAMINE; MOOD STABILIZER; OPIATE ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; HAMILTON SCALE; HEADACHE; HUMAN; IMPULSE CONTROL DISORDER; MALE; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; PATHOLOGICAL GAMBLING; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SELF REPORT; SINGLE BLIND PROCEDURE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VERTIGO;

ADOLESCENT; ADULT; FLUVOXAMINE; FRUCTOSE; GAMBLING; HUMANS; IMPULSE CONTROL DISORDERS; MALE; MIDDLE AGED;

EID: 13944282674     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000152623.46474.07     Document Type: Article

References (30)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
2. World Health Organization. The ICD-10 Classification of Mental & Behavioural Disorders. Geneva, World Health Organization, 1992.
3. Volberg RA. The prevalence and demographics of pathological gamblers: implications for public health. Am J Public Health. 1994;84:237-241.
4. Hollander E, Decaria CM, Finkell JN. A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry. 2000;47:813-817.
5. Hollander E, DeCaria CM, Mari E. Short-term single-blind fluvoxamine treatment of pathological gambling. Am J Psychiatry. 1998;155:1781-1783.
6. Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:44-48.
7. Hollander E, Frenkel M, DeCaria C, et al. Treatment of pathological gambling with clomipramine [letter] Am J Psychiatry. 1992;149:710-711.
8. Pallanti S, Quercioli L, Sood E, et al. Lithium and valproate treatment of pathological gambling: a randomized, single-blind study. J Clin Psychiatry. 2002;63:559-564.
9. Kim SW, Grant JE, Adson DE, et al. A double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2000;49:914-921.
10. Blanco C, Petkova E, Ibanez A, et al. A pilot placebo controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14:9-15.
11. Kim SW, Grant JE, Adson DE, et al. A double-blind, placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:501-507.
12. Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol. 2003;18:243-249.
13. Hollander E, Wong CM. Introduction: obsessive-compulsive spectrum disorder. J Clin Psychiatry. 1995;56(supplement 4):3-6.
14. Hollander E, Benzaquen SD. Is there a distinct OCD spectrum? CNS Spectr. 1996;1:17-26.
15. Langtry HD, Gillis JK, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs. 1997;54:752-773.
16. Ketter TA, Wang PW. The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. J Clin Psychiatry. 2003; 64:15-20.
17. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized placebo-controlled trial. Am J Psychiatry. 2003;160:255-261.
18. Dannon PN. Topiramate in the treatment of kleptomania: a case series and review of the literature. J Clin Neuropharmacol. 2003;26: 1-4.
19. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002;63:15-20.
20. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-59.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
22. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication 76-338. Rockville, MD: NIMH, 1976:218-222.
23. Hill CL, Heninger GR, Churney DS. The Yale-Brown obsessive compulsive scale: development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006.
24. Leisure HR, Blume S. The South Oaks Gambling Screen: A new instrument for the identification of pathological gamblers. Am J Psychiatry. 1987;144:1184-1188.
25. Potenza MN. The neurobiology of pathological gambling. Semin Clin Neuropsychiatry. 2001;6:217-226.
26. Bechara A. Risky business: emotion, decision making, pathological gambling and addiction. J Gambl Stud. 2003;19:23-51.
27. Kavoussi RJ, McElroy SL, Collins DJ. Divalproex sodium for impulsive aggressive behaviour in patients with personality disorder. J Clin Psychiatry. 1998;59:676-680.
28. Lydiard RB. The Role of GABA in anxiety disorders. J Clin Psychiatry. 2003;64(suppl 3):21-27.
29. Malcolm RJ. GABA systems, benzodiazepines, and substance dependence. J Clin Psychiatry. 2003;64(suppl 3):36-40.
30. Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex. 2000;10:318-325.